Medicenna Therapeutics stock holds at CAD 0.41 after SNO update
Published on 09/25/2026 at 07:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Medicenna Therapeutics stock stood at CAD 0.41 on the TSX on September 24, 2026, unchanged on the session and 79.2 percent below its 52-week high of CAD 1.97. On the same date, StockTitan reported that the company had secured an oral presentation slot for new bizaxofusp results.
SNO creates a clinical checkpoint
The abstract covers survival outcomes for bizaxofusp, formerly known as MDNA55, in unresectable, IDH-wildtype recurrent glioblastoma. The presentation is scheduled for the Society for Neuro-Oncology annual meeting in Philadelphia from November 12 to 15, 2026, giving the market a defined clinical date to track.
Medicenna is developing engineered cytokine therapies called Superkines for cancer and immune-related diseases. The company is also advancing MDNA11, a long-acting IL-2 program, and MDNA113, a bifunctional immunotherapy, according to StockTitan.
June results show continued cash use
For the three months ended June 30, 2026, Medicenna reported operating costs of CAD 5.4 million, down from CAD 5.5 million in the comparable 2025 period. The net loss was CAD 5.1 million, compared with CAD 4.9 million a year earlier, while the loss per share remained CAD 0.06, according to The Globe and Mail.
The comparison points to a modest reduction in quarterly spending, but the higher net loss places clinical execution and future financing among the key variables for the biotechnology company.
Trading remains below the yearly high
Medicenna had a market capitalization of CAD 31,435,007 on September 24, 2026. Trading volume was 1,537 shares against an average volume of 49,037, while the 52-week range stood at CAD 0.34 to CAD 1.97.
For investors, the November presentation date and the distance from the yearly high provide two concrete reference points. The TSX quote was CAD 0.41 on September 24, 2026.
Medicenna Therapeutics stock facts
- Company: Medicenna Therapeutics Corp.
- Ticker: MDNA
- Trading venue: TSX
- Price as of September 24, 2026: CAD 0.41
- Market capitalization: CAD 31,435,007 as of September 24, 2026
- 52-week range: CAD 0.34-1.97 as of September 24, 2026
- Sector / Industry: Healthcare / Biotechnology
